<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="section" /><meta name="keywords" content="Skin preparations: corticosteroids; Corticosteroids: skin: eczema; Adrenal: suppression: topical corticosteroids; Angular cheilitis: inflammation; Cheilitis, angular: inflammation; Corticosteroids: skin: psoriasis; Psoriasis: corticosteroids; Fingertip unit; FTU see Fingertip unit; Corticosteroids: skin: suitable quantities" /><meta name="IX" content="Skin preparations: corticosteroids; Corticosteroids: skin: eczema; Adrenal: suppression: topical corticosteroids; Angular cheilitis: inflammation; Cheilitis, angular: inflammation; Corticosteroids: skin: psoriasis; Psoriasis: corticosteroids; Fingertip unit; Corticosteroids: skin: suitable quantities" /><meta name="IXN" content="FTU see Fingertip unit" /><title>13.4 Topical corticosteroids: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="5837.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="5837.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=5837.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2080.htm">13 Skin</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="5833.htm" title="Previous: TOPICAL ANTIHISTAMINES">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="129041.htm" title="Next: Topical corticosteroid preparation potencies">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_5837">13.4 Topical corticosteroids</h1><?highlighter on?><div id="pC" class="jN"><div><div id="_5837.8"><p>Topical corticosteroids are used for the treatment of
inflammatory conditions of the skin (other than those arising from
an infection), in particular eczema (<a title="sub-section: Preparations for eczema" href="5938.htm#_5938">section 13.5.1</a>), contact dermatitis, <a title="target-block: Insect stings" href="29569.htm#_29569.3">insect stings</a>, and eczema of scabies (<a title="monograph-family: Scabies" href="14068.htm#_14068">section 13.10.4</a>). Corticosteroids suppress
the inflammatory reaction during use; they are not curative and on
discontinuation a rebound exacerbation of the condition may occur<span id="_5837.12"></span>. They are generally used to relieve symptoms and suppress
signs of the disorder when other measures such as emollients are ineffective.</p><p>Topical corticosteroids are of no value in the
treatment of urticaria and they are <b>contra-indicated</b> in rosacea; they may worsen ulcerated or secondarily infected lesions<span id="_5837.11"></span>. They should not be used indiscriminately in pruritus
(where they will only benefit if inflammation is causing the itch) and are <b>not</b> recommended for acne vulgaris.</p></div><p>Systemic or very potent topical corticosteroids
should be avoided or given only under specialist supervision in <i>psoriasis</i> because, although they may suppress the psoriasis
in the short term, relapse or vigorous rebound occurs on withdrawal
(sometimes precipitating severe pustular psoriasis). For the role
of topical corticosteroids in the treatment of psoriasis, see section <a title="BNF:sub-section: Preparations for psoriasis" href="5974.htm#_5974">13.5.2</a>.</p><p>In general, the most potent topical corticosteroids should be
reserved for recalcitrant dermatoses such as <i>chronic discoid
lupus erythematosus</i>, <i>lichen simplex chronicus</i>, <i>hypertrophic lichen planus</i>, and <i>palmoplantar
pustulosis</i>. Potent corticosteroids should generally be avoided
on the face and skin flexures, but specialists occasionally prescribe
them for use on these areas in certain circumstances.</p><p>When topical treatment has failed, intralesional corticosteroid
injections (<a title="sub-sub-section: Local corticosteroid injections" href="5272.htm#_5272">section 10.1.2.2</a>) may
be used. These are more effective than the very potent topical corticosteroid
preparations and should be reserved for severe cases where there are
localised lesions such as <i>keloid scars</i>, <i>hypertrophic
lichen planus</i>, or <i>localised alopecia areata</i>.</p><div id="_5837.4"><div class="cAZ"><h2>Perioral lesions</h2> <p class="cAX"><b><span>Hydrocortisone</span></b> cream 1% can be used for up to 7 days to treat uninfected
inflammatory lesions on the lips. <b><span>Hydrocortisone</span> and <span>miconazole</span></b> cream or ointment is
useful where infection by susceptible organisms and inflammation co-exist,
particularly for initial treatment (up to 7 days) e.g. in angular cheilitis
(see also <a title="target-block: Angular cheilitis" href="5702.htm#_5702.1">section 12.3.2</a>). Organisms
susceptible to <span>miconazole</span> include <span class="cAC">Candida</span> spp. and many Gram-positive bacteria including streptococci and
staphylococci. </p></div></div><div class="cAZ"><h2>Children</h2> <p class="cAX">Children, especially infants, are particularly
susceptible to side-effects. However, concern about the safety of
topical corticosteroids in children should not result in the child
being undertreated. The aim is to control the condition as well as
possible; inadequate treatment will perpetuate the condition. A mild
corticosteroid such as hydrocortisone 0.5% or 1% is useful for treating
nappy rash (<a title="sub-section: Barrier preparations" href="5809.htm#_5809">section 13.2.2</a>) and hydrocortisone 1% for atopic
eczema in childhood (<a title="sub-section: Preparations for eczema" href="5938.htm#_5938">section 13.5.1</a>). A moderately potent or potent
corticosteroid may be appropriate for severe atopic eczema on the
limbs, for 1–2 weeks only, switching to a less potent preparation
as the condition improves. In an acute flare-up of atopic eczema,
it may be appropriate to use more potent formulations of topical corticosteroids
for a short period to regain control of the condition. A very potent
corticosteroid should be initiated under the supervision of a specialist.
Continuous daily application of a mild corticosteroid such as hydrocortisone
1% is equivalent to a potent corticosteroid such as betamethasone
0.1% applied intermittently. Carers of young children should be advised
that treatment should <b>not</b> necessarily be reserved
to ‘treat only the worst areas’ and they may need to be advised that
patient information leaflets may contain inappropriate advice for
the patient’s condition.</p></div><div class="cAZ"><h2>Choice of formulation</h2> <p class="cAX">Water-miscible  corticosteroid <i>creams</i> are suitable for moist or weeping lesions whereas <i>ointments</i> are generally chosen for dry, lichenified or scaly
lesions or where a more occlusive effect is required. <i>Lotions</i> may be useful when minimal application to a large or hair-bearing
area is required or for the treatment of exudative lesions. <i>Occlusive polythene or hydrocolloid dressings</i> increase absorption,
but also increase the risk of side-effects; they are therefore used
only under supervision on a short-term basis for areas of very thick
skin (such as the palms and soles). The inclusion of urea or salicylic
acid also increases the penetration of the corticosteroid.</p><p>In the BNF topical corticosteroids for the skin are categorised
as ‘mild’, ‘moderately potent’, ‘potent’ or ‘very potent’ (see <a title="monograph-family: Topical corticosteroid preparation potencies" href="129041.htm#_129041">Topical corticosteroid preparation
potencies</a>); the <b>least potent</b> preparation which is effective should be chosen but dilution should
be avoided whenever possible.</p></div><div id="_5837.5"><div class="cAZ" id="_1.9"><h2>Cautions</h2> <p class="cAX"><span id="_5837.10">Avoid prolonged use of
a topical corticosteroid on the face (and keep away from eyes</span>). In
children avoid prolonged use and use potent or very potent corticosteroids under
specialist supervision; extreme caution is required in dermatoses of infancy
including nappy rash—treatment should be limited to 5–7 days.</p><div class="cAR"><h3>Psoriasis</h3> <p class="cAX">The use of potent
or very potent corticosteroids in psoriasis can result in rebound
relapse, development of generalised pustular psoriasis, and local
and systemic toxicity.</p></div></div></div><div class="cAZ" id="_5837.6"><h2>Contra-indications</h2> <p class="cAX"><span id="_5837.13">Topical corticosteroids are contra-indicated in untreated bacterial,
fungal, or viral skin lesions, in acne, in rosacea</span>, and in perioral dermatitis; potent corticosteroids are contra-indicated in widespread
plaque psoriasis (see notes above).</p></div><div id="_215460"><div class="cAZ"><h2>Side-effects</h2> <p class="cAX"><i>Mild</i> and <i>moderately potent</i> topical corticosteroids are associated
with few side-effects but care is required in the use of <i>potent</i> and <i>very potent</i> corticosteroids. Absorption through
the skin can rarely cause adrenal suppression and even Cushing’s syndrome
(<a title="topic: Disadvantages of corticosteroids" href="4256.htm#_4256">section 6.3.2</a>), depending on the area of the
body being treated and the duration of treatment. Absorption is greatest
where the skin is thin or raw, and from intertriginous areas; it is
increased by occlusion. Local side-effects include:</p><ul class="cBF"><li><p class="cQ">spread and worsening of untreated infection;</p></li><li><p class="cQ">thinning of the skin which may be restored over a period
after stopping treatment but the original structure may never return;</p></li><li><p class="cQ">irreversible striae atrophicae and telangiectasia;</p></li><li><p class="cQ">contact dermatitis;</p></li><li><p class="cQ">perioral dermatitis;</p></li><li><p class="cQ">acne, or worsening of acne or rosacea;</p></li><li><p class="cQ">mild depigmentation which may be reversible;</p></li><li><p class="cQ">hypertrichosis also reported.</p></li></ul><div class="cN"><p>In order to minimise the side-effects of a topical
corticosteroid, it is important to apply it <b>thinly</b> to affected areas <b>only</b>, no more frequently than <b>twice daily</b>, and to use the least potent formulation which
is fully effective.</p></div></div></div><div id="_5837.9"><div class="cAZ" id="_200820"><h2>Application</h2> <p class="cAX">Topical corticosteroid preparations should be applied no more frequently than twice daily; once daily
is often sufficient.</p> <p class="cAX">Topical corticosteroids should be spread thinly on the skin but in
sufficient quantity to cover the affected areas. The length of cream
or ointment expelled from a tube may be used to specify the quantity
to be applied to a given area of skin. This length can be measured
in terms of a <i>fingertip unit</i> (the distance from the tip of the adult index
finger to the first crease). One fingertip unit (approximately 500 mg)
is sufficient to cover an area that is twice that of the flat adult
palm.</p><div class="cBM" id="_tb0029">Suitable quantities of corticosteroid preparations to be prescribed
for specific areas of the body</div><table class="table" summary="Corticosteroids: skin: suitable quantitiesSuitable quantities of corticosteroid preparations to be prescribed&#xA;for specific areas of the body" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /></colgroup><thead><tr><th style="border-bottom: 1pt solid ; "> </th><th style="border-bottom: 1pt solid ; ">Creams and Ointments</th></tr></thead><tbody><tr><td style="">Face and neck</td><td style="">15 to 30 g</td></tr><tr><td style="">Both hands</td><td style="">15 to 30 g</td></tr><tr><td style="">Scalp</td><td style="">15 to 30 g</td></tr><tr><td style="">Both arms</td><td style="">30 to 60 g</td></tr><tr><td style="">Both legs</td><td style="">100 g</td></tr><tr><td style="">Trunk</td><td style="">100 g</td></tr><tr><td style="border-bottom: 1pt solid ; ">Groins and genitalia</td><td style="border-bottom: 1pt solid ; ">15 to 30 g</td></tr><tr><td style="" colspan="2">These amounts are usually suitable for an adult for a single daily application for 2 weeks</td></tr></tbody></table></div></div><div id="_204279"><p>If a patient is using topical corticosteroids of different potencies,
the patient should be told when to use each corticosteroid. The potency
of each topical corticosteroid (see <a title="monograph-family: Topical corticosteroid preparation potencies" href="129041.htm#_129041">Topical Corticosteroid Preparation
Potencies</a>) should be included on the label with the directions for use. The
label should be attached to the container (for example, the tube)
rather than the outer packaging.</p><p>Mixing topical preparations on the skin should be avoided where
possible; several minutes should elapse between application of different
preparations.</p></div><div id="_207922"><div class="cAZ"><h2>Compound preparations</h2> <p class="cAX">The advantages of including
other substances (such as antibacterials or antifungals) with corticosteroids
in topical preparations are uncertain, but such combinations may have
a place where inflammatory skin conditions are associated with bacterial
or fungal infection, such as infected eczema. In these cases the antimicrobial
drug should be chosen according to the sensitivity of the infecting
organism and used regularly for a short period (typically twice daily
for 1 week). Longer use increases the likelihood of resistance and
of sensitisation.</p><p>The keratolytic effect of salicylic acid facilitates the absorption
of topical corticosteroids; however, excessive and prolonged use of
topical preparations containing salicylic acid may cause salicylism.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="129041.htm" title="Topical corticosteroid preparation potencies">Topical corticosteroid preparation potencies</a></li><li id="_5838"><a href="5838.htm" title="HYDROCORTISONE">HYDROCORTISONE</a></li><li id="_5868"><a href="5868.htm" title="HYDROCORTISONE BUTYRATE">HYDROCORTISONE BUTYRATE</a></li><li id="_5872"><a href="5872.htm" title="ALCLOMETASONE DIPROPIONATE">ALCLOMETASONE DIPROPIONATE</a></li><li id="_203251"><a href="203251.htm" title="BECLOMETASONE DIPROPIONATE">BECLOMETASONE DIPROPIONATE</a></li><li id="_5876"><a href="5876.htm" title="BETAMETHASONE ESTERS">BETAMETHASONE ESTERS</a></li><li id="_5890"><a href="5890.htm" title="CLOBETASOL PROPIONATE">CLOBETASOL PROPIONATE</a></li><li id="_5894"><a href="5894.htm" title="CLOBETASONE BUTYRATE">CLOBETASONE BUTYRATE</a></li><li id="_5900"><a href="5900.htm" title="DIFLUCORTOLONE VALERATE">DIFLUCORTOLONE VALERATE</a></li><li id="_5917"><a href="5917.htm" title="FLUDROXYCORTIDE">FLUDROXYCORTIDE</a></li><li id="_5905"><a href="5905.htm" title="FLUOCINOLONE ACETONIDE">FLUOCINOLONE ACETONIDE</a></li><li id="_5912"><a href="5912.htm" title="FLUOCINONIDE">FLUOCINONIDE</a></li><li id="_5914"><a href="5914.htm" title="FLUOCORTOLONE">FLUOCORTOLONE</a></li><li id="_19232"><a href="19232.htm" title="FLUTICASONE PROPIONATE">FLUTICASONE PROPIONATE</a></li><li id="_5926"><a href="5926.htm" title="MOMETASONE FUROATE">MOMETASONE FUROATE</a></li><li id="_5928"><a href="5928.htm" title="TRIAMCINOLONE ACETONIDE">TRIAMCINOLONE ACETONIDE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="5833.htm">Previous: TOPICAL ANTIHISTAMINES</a> | <a class="top" href="5837.htm#">Top</a> | <a accesskey="]" href="129041.htm">Next: Topical corticosteroid preparation potencies</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>